Obstructive Chronic Bronchitis With Acute Exacerbation Clinical Trial
— STICOPDOfficial title:
a New and Non Invasive Method to Calculate STI ( Systolic Time Intervals) Combined to Valsalva Maneuver in Patient With Acute Exacerbation of COPD
NCT number | NCT02481908 |
Other study ID # | STI in COPD |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 2012 |
Est. completion date | December 2013 |
Verified date | September 2020 |
Source | University of Monastir |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The aim of this investigation was to assess the value of Systolic Time Intervals (STIs) as a method of detecting Left Ventricular Dysfunction (LVD) in patients admitted to the emergency department for cute exacerbations of chronic obstructive pulmonary disease (AECOPD) and whether STIs measured under Valsalva manoeuver (VM) could improve the distinction between patients with LVD and those without LVD.
Status | Completed |
Enrollment | 189 |
Est. completion date | December 2013 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Oxygen Saturation (SPO2) <90%, - Respiratory Rate >25c/min, - PaCO2 > 6 kPa et pH< 7.35. Exclusion Criteria: - Neurological distress and hemodynamic instability - Confusion, agitation - pneumothorax - Non cooperative patients - Refusal of consent |
Country | Name | City | State |
---|---|---|---|
Tunisia | CHU Fattouma Bourguiba | Monastir |
Lead Sponsor | Collaborator |
---|---|
University of Monastir |
Tunisia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | diagnosis of left ventricular dysfunction | Systolic time intervals measured at baseline and under Valsalva maneuver | during the first day admission in emergency department |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02125747 -
Respiratory Therapy in COPD Exacerbations
|
N/A |